| Disaggregation of revenue by product and by geographic area |
Revenues were as follows (in millions): | | | | | | | | | | | | | | | | Year ended December 31, 2019 | | | U.S. | | ROW | | Total | Enbrel® (etanercept) | | $ | 5,050 |
| | $ | 176 |
| | $ | 5,226 |
| Neulasta® (pegfilgrastim) | | 2,814 |
| | 407 |
| | 3,221 |
| Prolia® (denosumab) | | 1,772 |
| | 900 |
| | 2,672 |
| XGEVA® (denosumab) | | 1,457 |
| | 478 |
| | 1,935 |
| Aranesp® (darbepoetin alfa) | | 758 |
| | 971 |
| | 1,729 |
| KYPROLIS® (carfilzomib) | | 654 |
| | 390 |
| | 1,044 |
| EPOGEN® (epoetin alfa) | | 867 |
| | — |
| | 867 |
| Sensipar®/Mimpara® (cinacalcet) | | 252 |
| | 299 |
| | 551 |
| Other products | | 2,907 |
| | 2,052 |
| | 4,959 |
| Total product sales(1) | | 16,531 |
| | 5,673 |
| | 22,204 |
| Other revenues | | 693 |
| | 465 |
| | 1,158 |
| Total revenues | | $ | 17,224 |
| | $ | 6,138 |
| | $ | 23,362 |
|
| | | | | | | | | | | | | | | | Year ended December 31, 2018 | | | U.S. | | ROW | | Total | ENBREL | | $ | 4,807 |
| | $ | 207 |
| | $ | 5,014 |
| Neulasta® | | 3,866 |
| | 609 |
| | 4,475 |
| Prolia® | | 1,500 |
| | 791 |
| | 2,291 |
| Aranesp® | | 942 |
| | 935 |
| | 1,877 |
| XGEVA® | | 1,338 |
| | 448 |
| | 1,786 |
| Sensipar®/Mimpara® | | 1,436 |
| | 338 |
| | 1,774 |
| EPOGEN® | | 1,010 |
|
| — |
| | 1,010 |
| KYPROLIS® | | 583 |
| | 385 |
| | 968 |
| Other products | | 1,947 |
| | 1,391 |
| | 3,338 |
| Total product sales(1) | | 17,429 |
| | 5,104 |
| | 22,533 |
| Other revenues | | 929 |
| | 285 |
| | 1,214 |
| Total revenues | | $ | 18,358 |
| | $ | 5,389 |
| | $ | 23,747 |
|
| | | | | | | | | | | | | | | | Year ended December 31, 2017 | | | U.S. | | ROW | | Total | ENBREL | | $ | 5,206 |
| | $ | 227 |
| | $ | 5,433 |
| Neulasta® | | 3,931 |
| | 603 |
| | 4,534 |
| Aranesp® | | 1,114 |
| | 939 |
| | 2,053 |
| Prolia® | | 1,272 |
| | 696 |
| | 1,968 |
| Sensipar®/Mimpara® | | 1,374 |
| | 344 |
| | 1,718 |
| XGEVA® | | 1,157 |
| | 418 |
| | 1,575 |
| EPOGEN® | | 1,096 |
| | — |
| | 1,096 |
| KYPROLIS® | | 562 |
| | 273 |
| | 835 |
| Other products | | 1,419 |
| | 1,164 |
| | 2,583 |
| Total product sales(1) | | 17,131 |
| | 4,664 |
| | 21,795 |
| Other revenues | | 898 |
| | 156 |
| | 1,054 |
| Total revenues | | $ | 18,029 |
| | $ | 4,820 |
| | $ | 22,849 |
|
(1) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019, 2018 and 2017.
|
| Revenues earned from major customers |
Certain information with respect to these customers was as follows (dollar amounts in millions): | | | | | | | | | | | | | | Years ended December 31, | | 2019 | | 2018 | | 2017 | AmerisourceBergen Corporation: | | | | | | Gross product sales | $ | 12,301 |
| | $ | 12,091 |
| | $ | 10,742 |
| % of total gross revenues | 33 | % | | 33 | % | | 31 | % | McKesson Corporation: | | | | | | Gross product sales | $ | 11,795 |
| | $ | 11,434 |
| | 10,625 |
| % of total gross revenues | 31 | % | | 31 | % | | 30 | % | Cardinal Health, Inc.: | | | | | | Gross product sales | $ | 6,538 |
| | $ | 7,475 |
| | $ | 7,049 |
| % of total gross revenues | 17 | % | | 20 | % | | 20 | % |
|